The new cancer drugs don't fight harder — they strip the disguise

Biotech & Longevity 5 min 40 sources

At the world's largest cancer meeting, the standout results came from treatments that unmask tumours so the immune system can find them. Plus: weight-loss drugs keep showing benefits far beyond weight, gene therapy gets a regulatory tailwind, and an honest answer on how long humans can live — we don't know.

Key takeaways

The standout cancer results at the world's largest oncology meeting came from drugs that unmask tumours so the immune system can find them — recognition, not extra force — though the trials are early and small.
Weight-loss drugs like Ozempic keep showing benefits far beyond weight, from lower breast-cancer risk to fewer overdoses and knee surgeries, but most of this evidence is observational and can't yet prove cause.
The honest longevity story is humility: a major review says we don't know how long humans can live, and a clean ageing study extended lifespan in male mice by 12% but not in females — and it was, as usual, in mice.

At the big cancer meeting, a theme: make the hidden visible

The American Society of Clinical Oncology — the world’s largest cancer conference — met in Chicago this week, and its most striking results shared a logic [5]. The immune system can kill cancer. The trouble is that cancer learns to hide from it. Several of the week’s trials worked not by hitting tumours harder, but by stripping that disguise.

A tablet developed in Oxford, GRWD5769, is designed to stop cancer cells concealing themselves from the immune system [5]. In an early trial across the UK, France, Spain and Australia, 83 patients with cervical, bladder, liver, bowel, lung or head and neck cancers took it alongside an immunotherapy drug, cemiplimab [5]. All had already run out of options — immunotherapy had failed or stopped working. Tumours shrank in 26 patients; 15 saw reductions of at least 30% [5]. One participant, Pat Brogan, 68, diagnosed with stage four lung cancer in 2021, has watched his tumours shrink by nearly a third [16].

A separate injection, amivantamab, brought what one oncologist called “unprecedentedly strong responses” [26]. Among 102 head and neck cancer patients whose disease had resisted both chemotherapy and immunotherapy, tumours shrank or disappeared in 43 — and were eradicated entirely in 15 [26].

And in bowel cancer, a UK trial called NEOPRISM-CRC gave the immunotherapy pembrolizumab before surgery to 32 patients with a particular genetic profile (called MMR-deficient, found in 10–15% of cases) [15]. None have relapsed after nearly three years, and the treatment removed the need for chemotherapy [15].

The caveats matter. These are early, mostly small trials, presented at a meeting rather than fully published. They enrolled selected patients, and a strong response is not yet a proven cure. But the direction is consistent: the gain comes from recognition, not extra force.

The weight-loss drugs that keep doing more than weight loss

The other theme this week was a class of drugs that refuses to stay in its lane. GLP-1 medicines — including Ozempic and Wegovy — mimic a natural gut hormone that regulates appetite and blood sugar [8]. They were built for diabetes and obesity. They keep turning up linked to other benefits.

At the same cancer meeting, several studies tied GLP-1 use to lower cancer risk: one analysis of 110,000 women found those taking the drugs were 30% less likely to develop breast cancer [8]. A study of more than 600,000 US veterans linked the drugs to lower rates of addiction and fewer overdoses across alcohol, nicotine and opioids [13]. Another, drawn from 6.8 million people with knee arthritis, suggested years of use could head off thousands of knee replacements by easing the load on the joints [23].

Read these carefully. They are mostly retrospective — they compare people who happened to take the drugs against those who didn’t, which can’t prove the drug caused the difference. The people who get prescribed and stay on these medicines may differ in other ways. Still, the pattern is hard to ignore, and it hints at something real: a single lever on metabolism seems to move things we file under separate diseases.

Two footnotes. Researchers in Sweden reported an early-stage pill that burns fat by revving up muscle metabolism rather than suppressing appetite — tested so far in animals and 73 people [22]. And access is shifting: Canada became the first G7 country to approve a generic version of semaglutide, at less than a third of the price, while in the US patents keep low-cost copies years away [24].

Gene therapy gets a regulatory tailwind

The US Food and Drug Administration, the country’s drug regulator, issued draft guidance meant to speed up cell and gene therapies for rare, life-threatening diseases [12]. The idea is to let developers reuse established manufacturing and safety knowledge instead of repeating tests from scratch — cutting time without, the agency says, cutting the safety bar [12].

The science kept pace. Researchers reported a phase 1 trial — the first, smallest human test, mainly checking safety — of an AAV gene therapy for a severe inherited high-cholesterol disorder, delivering a working gene via a harmless virus [17]. And a study in Cancer Discovery pinpointed a single protein, NFIL3, that wears out CAR-T cells — engineered immune cells — over time; switching it off kept them fighting longer in animals [1]. Both are early, and animal or first-in-human results often don’t hold up. But each names a concrete next step.

Longevity: an honest “we don’t know,” and a clock in mice

Against a market full of anti-ageing claims, a Nature review of the new book Morbid landed a blunt message: we genuinely do not know how long humans can live, and much of the longevity field rests on shaky demographic data [27]. It is a useful corrective — the confident numbers usually aren’t earned.

The lab work is more modest, and more honest about its limits. A careful study fed 528 mice on time-restricted schedules — all their food within an 8- or 12-hour nightly window [29]. The tightest window improved health measures across the board and extended median lifespan in male mice by 12% — but did not extend lifespan in females at all [29]. It is a clean result, and a reminder of how often biology splits by sex. It is also, as ever, in mice; most things that work in mice never work in people.

A neglected outbreak gets a shot

End on the story the headlines mostly skipped. An outbreak of Bundibugyo virus — a strain of Ebola — has recorded more than 900 suspected cases and over 220 suspected deaths [33]. This week Moderna joined a global coalition, CEPI, to develop a vaccine against it, with up to $50 million committed for early testing, alongside candidates from Oxford and others [33]. There is no approved Bundibugyo vaccine yet; these are first steps. But it is the week’s clearest reminder that the same tools chasing cancer and ageing are also, quietly, racing a virus most people will never hear of.

02 · Lesson · why it matters

The problem was never the fight. It was the seeing.

When a strong defender keeps losing, the weakness is often not its power but its eyesight — it cannot act on what it cannot see.

A drug that doesn’t attack the cancer

The strangest thing about this week’s standout cancer results is what the new drugs don’t do. They don’t poison the tumour. They don’t hit it harder. They make it visible.

The patients had already lost the usual fights. Chemotherapy, then immunotherapy — and the cancer came back. Then a drug that does almost nothing to the cancer directly, given alongside the same immunotherapy that had failed, and suddenly tumours shrink. In some patients they vanish.

How does adding a drug that doesn’t attack the cancer make the attack work? The answer is the whole lesson.

The army was never the problem

Your immune system is an extraordinary killer. It hunts down infected and damaged cells every day and destroys them. Against many cancers it is more than strong enough.

Cancer’s trick is not strength. It is disguise. Tumour cells learn to display “don’t look here” signals — a kind of invisibility cloak — so the patrolling immune cells slide right past. The army is at full strength, marching through the right streets, and walking past the enemy because it can’t tell friend from foe.

So for decades the instinct was to bring more force. Chemotherapy is essentially carpet-bombing: poison everything that divides quickly and hope the cancer dies before the patient does. It works, sometimes, at a cost to every fast-growing tissue in the body.

The new drugs make a different bet. They assume the firepower was always sufficient. What was missing was sight. Strip the cloak, and the immune system — unchanged, unaided, exactly as strong as it always was — finds the tumour and clears it.

Recognition, not firepower

Name the pattern, because it reaches far past oncology: a capable defender that keeps losing usually has a recognition problem, not a strength problem.

It is an easy thing to get backwards, because force is visible and recognition is not. When something keeps going wrong, the obvious move is to push harder — more effort, more money, more pressure, a bigger hammer. Pushing harder feels like doing something. And when the real failure is that you can’t see the actual problem, pushing harder mostly just damages everything around it, the way carpet-bombing harms healthy tissue.

A team that keeps missing its deadlines may not need to work longer hours; it may need to see which one hidden dependency stalls everything. A person who can’t fix a recurring fight may not need more willpower; they may need to name the thing underneath it that neither side has said aloud. A market keeps mispricing a risk not because no one is trying, but because the risk is structured to stay invisible until it isn’t. In each case the defender is strong enough. The enemy is just wearing a cloak.

The honest limits

Hold the pattern lightly, though, because seeing is not the same as solving.

These cancer drugs are early trials, in small groups of selected patients. They unmask some tumours and not others. Removing a disguise gives a capable system a fighting chance; it does not guarantee a win. And cancer, like most real adversaries, adapts — it will look for new ways to hide.

The same caution applies everywhere the pattern does. Naming a hidden problem is the start of the work, not the end of it. The point is not that visibility is magic. It is that you cannot fight what you cannot find — so when a strong response keeps failing, the most useful question is often not “how do I hit harder?” but “what am I not seeing?”

Where to spend the next effort

Watch which way the instinct pulls when something resists you. Toward more force, almost always — it is the move that feels like progress.

The week’s quiet correction is to check the other thing first. Before you add power, ask whether the defender already has enough, and the real gap is recognition. Sometimes the breakthrough isn’t a stronger weapon. It’s removing whatever is keeping the threat invisible — and then trusting the strength you already had to do its work.

03 · Lab · your turn

The Cloaked Tumour

Rehearse choosing recognition over firepower against a hidden threat, and feel why a strong defender that can't see keeps losing.